Royalty Report: Drugs, Cancer, Disease – Collection: 282139

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Diagnostic
  • Monitoring
  • Pharmaceuticals
  • Bacterial Infection
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282139

License Grant
Under the terms of the patent license agreement, the Company acquired substantially all of the assets of Party C, including Party C’s rights to Brilacidin under a patent license agreement from an University.
License Property
Brilacidin, the lead drug in a new class of compounds called defensin-mimetics, and Kevetrin (thioureidobutyronitrile), is the lead anti-cancer compound.
Field of Use
Brilacidin is for the indication of Oral Mucositis and Kevetrin for the indication of ovarian cancer.  Brilacidin is for localized treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).

IPSCIO Record ID: 275417

License Grant
Licensor grants the Licensee of Italy
—   an exclusive license, with the right to grant sublicenses, under Licensor’s right, title and interest in and to the Licensor Patents, the Licensor Know-How, the Joint IP, the Joint Patents and the New IP owned or Controlled by Licensor specifically for and limited to Develop the Product in the Licensee Territory for the Indication, and
—  an exclusive license, with the right to grant sublicenses, under Licensor’s right, title and interest in and to the Licensor Patents, the Licensor Know-How, the Joint IP, the Joint Patents and the New IP owned or Controlled by Licensor to Manufacture, have Manufactured and Commercialize the Product in the Licensee Territory for the Indication.
License Property
Compound means Licensor’s proprietary molecule known as Brilacidin, including any back-up compounds and analogues (including, prodrugs, metabolites, complexes, degradants, impurities, mixtures and other combinations) their salts, solvates, hydrates, stereoisomers, crystalline and amorphous forms, owned or Controlled by Licensor as of the Effective Date or during the Term.
Field of Use
The filed of use is for the prevention, treatment, amelioration, diagnosis or monitoring of Ulcerative Proctitis/Proctosigmoiditis (UP/UPS) using finished formulation(s) for local administration (e.g., gel, foam, enema) to the rectum and/or colon.

IPSCIO Record ID: 935

License Grant
The original agreement assigned to Licensee all right, title and interest to a Compound and patents thereon known as Kevetrin.

After executing the Prior Agreement and filing for and obtaining Kevetrin Patents, Licensor, two individuals, and Licensee learned that a joint inventor of Kevetrin was inadvertently omitted from the Kevetrin Patents.  The Licnesor then acquired the entire interest of the joint inventor in Kevetrin and the Kevetrin Patents and, consistent with the Prior Agreement, hereby assigns to Cellceutix all of the joint inventor’s right, title and interest in and to Kevetrin and the Kevetrin Patents.

License Property
Kevetrin means the substance identified by the chemical structure set forth in the U.S. Patent No. 8,338,454, all hydrates, salts and esters of that substance, all enantiomers of the substance, all mixtures of the foregoing, all substances developed using any of the foregoing as starting material, as intermediates or as a model or template, and all substances claimed in any Kevetrin Patent.

Kevetrin Patents means all patents and patent applications anywhere in the world that disclose and claim a Compound or its therapeutic uses, including U.S. Patent No. 8,338,454 (“’454 Patent”), all worldwide patent applications that rely for priority on the ‘454 Patent or on any of the applications from which the ‘454 Patent directly or indirectly issued (including U.S. Patent Application No. 13/685,879, filed November 27, 2012), all worldwide patents issuing from any of the foregoing  applications, and all reexaminations, reissues or extensions of any of the foregoing patents.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.